Skip to Content

Quintanrix

Active Substance: diphtheria toxoid / tetanus toxoid / inactivated Bordetella pertussis / hepatitis B surface antigen (rDNA) / Haemophilus influenzae type b polysaccharide
Common Name: diphtheria, tetanus, pertussis (whole cell), hepatitis B (rDNA) and Haemophilus influenzae type B conjugate vaccine (absorbed)
ATC Code: J07CA10
Marketing Authorisation Holder: GlaxoSmithKline Biologicals S.A.
Active Substance: diphtheria toxoid / tetanus toxoid / inactivated Bordetella pertussis / hepatitis B surface antigen (rDNA) / Haemophilus influenzae type b polysaccharide
Status: Withdrawn
Authorisation Date: 2005-02-17
Therapeutic Area: Meningitis, Haemophilus Hepatitis B Diphtheria Whooping Cough Immunization Tetanus
Pharmacotherapeutic Group: Vaccines

Therapeutic Indication

Quintanrix is indicated for primary immunisation of infants (during the first year of life) against diphtheria, tetanus, pertussis, hepatitis B and invasive disease caused by Haemophilus influenzae type b and for booster immunisation of young children during the second year of life.
The use of Quintanrix should be determined on the basis of official recommendations.

The marketing authorisation for Quintanrix has been withdrawn at the request of the marketing authorisation holder

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide